Share on facebook
Share on twitter
Share on pinterest
Share on telegram
Share on whatsapp
Share on email

Related Articles

ADVERTISEMENT

Both ixekizumab and brodalumab were associated with better clinical benefit than other biologic therapies over 12 weeks or 16 weeks of treatment for psoriasis, according to a meta-analysis.

“Cumulative clinical improvement and speed of improvement are important to psoriasis patients,” Richard B. Warren, MD, PhD, of the Salford Royal NHS Foundation Trust at the University of Manchester, Manchester NIHR Biomedical Research Centre in the U.K., and colleagues wrote. “Although cumulative life course impairment is a theoretical construct referring to the burden of disease over a long period of time, evaluating the cumulative

clinical benefit, even over the first 12 to 16 weeks of treatment, can improve understanding of the impact of treatment on the patient.”

Warren and colleagues conducted a systematic literature review to compare the cumulative benefits of biologics that had available data for 12 to 16 weeks of treatment in patients with moderate to severe psoriasis.

Eligible analyses were phase 3 trials that measured Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 responses.

The analysis included 714 studies, of which 245 were full-text publications and 469 were conference abstracts. The final data set included 28 articles that met criteria.

<a href="https://m3.healio.com/~/media/slack-news/stock Read More

ADVERTISEMENT

Leave a Replay

Recent Posts

Recent Posts

January Q&A from Instagram

Hello! I’m answering a pile of new questions about running, eating and my life. If you’re new to Run Eat Repeat – follow me on Instagram @RunEatRepeat . You can

Read More »

January Q&A from Instagram

Hello! I’m answering a pile of new questions about running, eating and my life. If you’re new to Run Eat Repeat – follow me on Instagram @RunEatRepeat . You can

Read More »

Latest Articles

Recommended 

Clippednews goes Social Media